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Abstract
Background: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive
form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines,
such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in
combination with trastuzumab – however, doxorubicin-related cardiotoxicity has limited its use. Many patients are
therefore never treated with anthracyclines, even upon disease progression, despite the potential for benefit.
MM-302 is a novel, HER2-targeted antibody–liposomal doxorubicin conjugate that specifically targets HER2overexpressing
cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be
effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity
observed with free doxorubicin formulations.
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Methods/Design: HERMIONE is an open-label, multicenter, randomized (1:1) Phase 2 trial of MM-302 plus trastuzumab
versus chemotherapy of physician’s choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned
to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. Key inclusion
criteria are: previous treatment with trastuzumab (with or without pertuzumab) in any setting; refractory or intolerant
to pertuzumab (refractory to pertuzumab defined as progression in the locally advanced or metastatic setting,
or disease recurrence during or within 12 months of completing pertuzumab-containing neoadjuvant and/or
adjuvant therapy); and disease progression on, or intolerant to, ado-trastuzumab emtansine for locally advanced or
metastatic disease. The trial is currently being conducted at sites in the USA, Canada, and Western Europe. Treatment
will be administered in 21-day cycles, and will be continued until disease progression or unacceptable toxicity.
The primary endpoint is independently assessed progression-free survival (PFS). Tumor response will be assessed
every 6 weeks, and defined according to RECIST v1.1. Secondary endpoints include investigator-assessed PFS,
overall survival (OS), OS rates at 6 months and 1 year, objective response rates, safety and tolerability, quality of
life, and the pharmacokinetic profile of MM-302 plus trastuzumab.
Discussion: The HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients
with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies
with a proven survival advantage.
Trial Registration: Clinicaltrials.gov identifier: NCT02213744. Registration date: 06AUG2014.
Keywords: Advanced/metastatic breast cancer, Antibody–conjugate, Doxorubicin, Cardiotoxicity, HERMIONE, Human
epidermal growth factor receptor 2/HER2/Erb2, HER2-targeted liposomal doxorubicin, Immunoliposome, MM302,
Trastuzumab
Background
Approximately 20 % of breast cancers are human epi-
dermal growth factor receptor 2 (HER2)-positive,
which represents a particularly aggressive subtype [1, 2].
HER2-targeted anticancer therapies such as trastuzumab,
pertuzumab, ado-trastuzumab emtansine (T-DM1), and
lapatinib have transformed the management and progno-
sis of HER2-positive advanced/metastatic breast cancer
[3–10]. Current standard of care is to continue HER2-
targeted therapy indefinitely (trastuzumab with changing
chemotherapy partners, or T-DM1 or lapatinib in combin-
ation with capecitabine) [11–15]. Nonetheless, disease
ultimately progresses in patients on standard therapies.
Evidence suggests that limited mechanistic diversity as-
sociated with repeated use of microtubule-targeting
chemotherapeutic agents, including taxanes (paclitaxel,
nab-paclitaxel, and docetaxel) and vinca domain-
binding agents (T-DM1, vinorelbine, and eribulin),
could contribute to their diminishing effectiveness,
owing to shared mechanisms of resistance [16]. Novel
treatment strategies are essential.
Advantages and limitations of existing anthracycline
formulations
Anthracyclines such as doxorubicin are effective for
managing HER2-positive breast cancer, particularly in
anthracycline-naïve patients. The trastuzumab regis-
tration study demonstrated increased efficacy with
trastuzumab plus an anthracycline-containing regimen
compared with an anthracycline-containing regimen
alone in advanced/metastatic breast cancer [17]. How-
ever, this study also reported substantial cardiotoxicity
when combining an anthracycline with trastuzumab:
cardiac dysfunction occurred in 27 % of patients who
received trastuzumab plus an anthracycline-based
regimen (with severe heart failure reported in 16 % of
patients), compared with 8 % for an anthracycline-
based regimen without trastuzumab, and 13 % for
paclitaxel plus trastuzumab. Furthermore, studies in
the adjuvant and neoadjuvant settings suggest equiva-
lent or greater efficacy of taxane-based regimens rela-
tive to anthracycline-based regimens in breast cancer
[18, 19]. These findings have led to a decline in
anthracycline use overall (Fig. 1), and particularly in
the adjuvant setting in HER2-positive advanced/meta-
static breast cancer [18, 20–24].
PEGylated (PLD; Doxil®/Caelyx®, Janssen) and non-
PEGylated (NPLD; Myocet®, Enzon Pharmaceuticals) li-
posomal doxorubicin formulations have been developed
that aim to overcome the challenges associated with
using free doxorubicin. Both PLD and NPLD have
shown reduced cardiotoxicity compared with free doxo-
rubicin [25–32]. Although PLD appears to be active in
this setting, PLD as a monotherapy or in combination
with trastuzumab is not considered a standard of care in
the treatment of HER2-positive advanced/metastatic
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breast cancer. In Europe, PLD monotherapy is approved
for metastatic breast cancer patients at high cardiac risk
[33], but in the USA, PLD has not been approved either
alone or in combination with trastuzumab. NPLD in
combination with trastuzumab and paclitaxel was not
superior to the combination of trastuzumab and pacli-
taxel in a Phase 3 study of first-line therapy for ad-
vanced/metastatic breast cancer [32].
MM-302 – a novel, HER2-targeted antibody–liposomal
doxorubicin conjugate
MM-302 is a novel, HER2-targeted antibody–liposomal
doxorubicin conjugate (Fig. 2) that specifically targets
HER2overexpressing cells, increasing delivery of doxo-
rubicin to tumor cells and limiting exposure to healthy
cells such as cardiomyocytes (Fig. 3). MM-302 is there-
fore designed potentially to be better tolerated than free
doxorubicin, and to be more effective than free doxo-
rubicin and existing liposomal formulations in HER2-
overexpressing tumors [34, 35]. In preclinical models,
MM-302 demonstrated superior antitumor activity
compared with both free doxorubicin and PLD [35].
Moreover, MM302 and trastuzumab bind to different
HER2 epitopes, and the combination of MM-302 and
trastuzumab demonstrated superior antitumor activity
to either agent alone in HER2overexpressing tumor
xenograft models (unpublished observations, Chris
Espelin, Shannon Leonard, and Elena Geretti; Merrimack
Pharmaceuticals, Inc., Cambridge, MA, USA). These find-
ings provided support for investigating the combination in
the clinical setting. Phase 1 data suggest that MM-302
alone or in combination with trastuzumab has promising
efficacy and a manageable safety profile in patients with
advanced HER2-positive breast cancer. In the population
treated with ≥30 mg/m2 MM-302 alone (n = 34) or com-
bined with either trastuzumab (n = 22) or trastuzumab
plus cyclophosphamide (n = 13), the objective response
rate was 11.3 % (n = 7/62) and median progression-free
survival (PFS) was 7.6 months (95 % CI: 3.6–10.9).
Increased efficacy was observed in the anthracycline-
naïve subgroup, with an objective response rate of
24.0 % (n = 6/25) and median PFS of 11.0 months
(95 % CI: 1.8–13.1) [36]. No cardiac adverse events
were reported with MM-302 monotherapy; in the
combination arms, cardiac adverse events were infre-
quent and none were serious adverse events [36].
Rationale for the HERMIONE trial
Given the high unmet need for novel treatment op-
tions for patients with HER2- positive metastatic
breast cancer that has progressed on pertuzumab,
trastuzumab, and T-DM1, and the promising activity
seen in the Phase 1 study, the Phase 2 HERMIONE
trial has been designed, with input from the US Food
and Drug Administration (FDA) and review by the
European Medicines Agency (EMA), to assess the ef-
ficacy and tolerability of MM-302 in combination
with trastuzumab, compared with chemotherapy of
physician's choice plus trastuzumab, in patients with
previously treated, anthracycline-naïve, HER2positive
locally advanced/metastatic breast cancer.
Methods/Design
Study design
HERMIONE is an open-label, multicenter, randomized
(1:1) Phase 2 trial of MM-302 plus trastuzumab
versus chemotherapy of physician’s choice (gemcita-
bine, capecitabine, or vinorelbine) plus trastuzumab
in anthracycline-naïve patients with locally advanced/
metastatic HER2-positive breast cancer (Clinical-
Trials.gov Identifier: NCT02213744). The trial is being
Fig. 1 Decline in the use of anthracyclines to manage breast cancer
[20]. Panels show monthly trends and fit curves of anthracycline and
taxane use among a 4458 Medicare patients and b 30 422 Marketscan
patients who were receiving adjuvant chemotherapy for breast cancer.
Figure reproduced with permission [Copyright permission request
is underway and the copyright line will be updated following
manuscript acceptance]
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conducted at sites in the USA, Canada, and Western
Europe. The trial design and treatment schedule are
summarized in Fig. 4.
Patients will be randomized according to a pre-
specified randomization scheme generated by an inde-
pendent statistician. Once patient eligibility for the study
has been confirmed, investigational sites will log into a
computerized interactive web response system to obtain
treatment arm assignment. Randomization will be strati-
fied based on world region (North America/Western
Europe/Other), presence of visceral disease (yes/no), and
number of prior lines of anticancer therapy for locally
advanced/metastatic disease (≤3/≥4).
The study will be performed according to the prin-
ciples of the Declaration of Helsinki, the International
Conference on Harmonization Guidance on Good
Clinical Practice, and the requirements of the US
FDA and/or local regulatory authorities regarding the
conduct of human clinical trials. All patients must
give written informed consent. Local Institutional Review
Board or Ethics Committee approval of the protocol, in-
formed consent document, and any other material used to
inform the patient about the nature of the trial has been
obtained for all participating centers.
Eligibility criteria
Key inclusion criteria are: histologically or cytologic-
ally confirmed invasive breast cancer that is centrally
confirmed as HER2-positive by American Society of
Clinical Oncology/College of American Pathologists
2013 guidelines [37]; documented locally advanced/
metastatic disease; prior treatment with trastuzumab
in any setting; refractory or intolerant to pertuzumab
(refractory to pertuzumab is defined as progression
on pertuzumab in the locally advanced or metastatic
setting, or development of disease recurrence during or
within 12 months of completing pertuzumab-containing
neoadjuvant and/or adjuvant therapy); disease progression
on, or intolerant to, T-DM1 treatment for locally advanced
or metastatic disease; not previously treated with an
anthracycline in any setting; aged ≥18 years; Eastern Co-
operative Oncology Group performance status 0 or 1; left
ventricular ejection fraction (LVEF) ≥50 %. Patients with
treated, stable, asymptomatic central nervous system
(CNS) metastases and who have not received steroid treat-
ment for 4 weeks prior to enrollment may be considered
for this trial. Further details of the study inclusion and ex-
clusion criteria are presented in Table 1, and examples of
the most common previous treatment pathways for eli-
gible patients are shown in Fig. 5. There is no restriction
on the number of prior lines of therapy for eligible
patients.
Study treatments
Treatment arms
Patients will be randomized to receive either MM-302
plus trastuzumab or chemotherapy of physician's choice
plus trastuzumab. In the experimental arm, patients will
receive MM-302 30 mg/m2 IV on day 1 of each 21-day
cycle, and trastuzumab 8 mg/kg IV (loading dose) and
Fig. 2 Schematic of MM-302, a novel HER2-targeted antibody–liposomal doxorubicin conjugate. MM-302 consists of doxorubicin encapsulated by
a liposome that is conjugated to an anti-HER2 scFv antibody via a polyethylene glycol spacer (PEG-DSPE). MM-302 thus directly targets PEGylated
liposomal doxorubicin to HER2-overexpressing tumor cells
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6 mg/kg IV (maintenance dose) on day 1 of each 21-day
cycle. In the control arm, physicians will select a
chemotherapy (limited to gemcitabine, capecitabine, or
vinorelbine) plus trastuzumab, as follows: gemcitabine
1000–1250 mg/m2 IV on days 1 and 8 of each 21-day
cycle; capecitabine 1000–1250 mg/m2 twice daily, ad-
ministered orally on days 1–14 of each 21-day cycle;
vinorelbine 25–30 mg/m2 IV on days 1 and 8 (and op-
tionally on day 15) of each 21-day cycle; trastuzumab
administration in the control arm is the same as in the
experimental arm. Treatment will be continued until
progression or intolerable toxicity. There will be no
crossover of control arm to receive study drug on
progression.
Dose modifications
Dose modification of study treatments is permitted to
manage toxicities. A maximum of two MM-302 dose re-
ductions (by 25 %) are permitted to manage hematologic
and non-hematologic adverse events. For hepatotox-
icity, the dose will be reduced to 15 mg/m2 if total
bilirubin is 1.2–3.0 mg/dL, and to 7.5 mg/m2 if total
bilirubin is >3.0 mg/dL. Any patients requiring a third
dose reduction will have MM-302 discontinued. Spe-
cific MM-302 dose modification criteria are also de-
fined for managing changes in LVEF. In case of
persistent asymptomatic LVEF decreases and congest-
ive heart failure, study treatment will be permanently
discontinued. Patients with confirmed symptoms of
congestive heart failure will also discontinue treat-
ment permanently.
Specific criteria to withhold/discontinue MM-302
treatment are also defined for managing LVEF changes.
MM-302 will be withheld if LVEF declines to ≤45 % or if
LVEF declines to 46–49 % and is ≥15 % points below
baseline. LVEF assessment will then be repeated after
3 weeks: if LVEF recovers sufficiently (LVEF ≥50 %, or
46–49 % and <15 % points below baseline), study
Fig. 3 Mechanism of action of MM-302. a MM-302 binds to HER2 extracellular subdomain I, whilst trastuzumab binds to subdomain IV. b MM-302
remains in circulation for long periods of time, providing an opportunity to accumulate in tumors via leaky vasculature. Once in the tumor
microenvironment, MM-302 binds specifically to tumor cells that overexpress HER2 (>200 000/cell) and undergoes receptor-mediated endocytosis,
releasing doxorubicin inside the cell. By contrast, the vasculature of the heart is more intact and prevents extravasation out of the blood vessels.
Furthermore, cardiomyocytes express HER2 below the threshold required for uptake; therefore, MM-302 does not inhibit HER2-mediated signaling in
cardiomyocytes [34, 35]
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treatment will be resumed, otherwise the patient will
permanently discontinue treatment.
Concomitant therapies
Patients may receive concomitant analgesics, antiemetics,
antidiarrheal antibiotics, antipyretics, hematopoietic
growth factors, and blood products as per physician dis-
cretion. For patients with bone metastases, standard of
care treatments such as bisphosphonates and denosumab
are permitted. The following therapies are not permitted
while on study treatment: other antineoplastic therapies;
radiotherapy (unless given for palliative reasons and with
the approval of the Medical Monitor); systemic prophy-
lactic corticosteroids prior to first administration of
MM-302; any other investigational therapies; and any
therapies that are prohibited from being given con-
comitantly with gemcitabine, capecitabine, or vinorel-
bine, as described in the respective national prescribing
information.
Study objectives
The primary objective is to determine whether the com-
bination of MM-302 plus trastuzumab improves PFS
(time from randomization until documented disease
progression or death) compared with chemotherapy of
physician's choice plus trastuzumab. PFS will be assessed
by a blinded independent review. Secondary endpoints
are investigator-assessed PFS; overall survival (OS; time
from randomization until death); OS rate at 6 months
and 1 year; time to treatment failure (time from
randomization until treatment discontinuation for any
reason, including disease progression, treatment tox-
icity, or death); objective response rate (patients with
confirmed complete or partial response); duration of
response (time from first, documented, confirmed ob-
jective response until objectively documented recur-
rent or progressive disease); safety profiles; and
pharmacokinetic exposure of MM-302 and trastuzu-
mab. Exploratory objectives include the correlation
between biomarkers and clinical outcome; time to
symptomatic progression; patient-reported outcomes
(Functional Assessment of Cancer Therapy-Breast
[FACT-B] and EuroQol [EQ]-5D); population pharma-
cokinetics of MM-302 including estimations of inter-
patient variability of pharmacokinetic parameters; rate
and time to development of CNS progression and
new CNS metastases; estimation of resources for hospital-
izations/hospital visits during the study and within 30 days
of the last dose of study treatment; and concordance be-
tween independently and investigator-assessed PFS. An
independent Cardiac Review Committee will monitor car-
diac safety, and a Data Safety Monitoring Board will moni-
tor the overall safety of the study.
Study assessments
Tumor response will be assessed by computed tomog-
raphy/magnetic resonance imaging at screening and
every 6 weeks from randomization, and will be de-
fined according to Response Evaluation Criteria In
Solid Tumors (RECIST) v1.1. Cardiotoxicity will be
assessed by monitoring LVEF at screening and every
6 weeks from randomization until 6 weeks after
Fig. 4 HERMIONE study design and assessment schedule
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treatment discontinuation. LVEF will be determined
by multiple-gated acquisition scan or echocardiogram,
with the same assessment method continued throughout
the study. Long-term cardiotoxicity will be assessed by re-
cording the occurrence of symptomatic heart failure in
the follow-up period of the study. Safety will be assessed
Table 1 Key inclusion and exclusion criteria for the Phase 2 HERMIONE study
Criteria Details
Inclusion criteria
Disease-specific • Histologically or cytologically confirmed invasive cancer of the breast, with documented locally
advanced/metastatic disease that is not amenable to resection with curative intent. Cancer must
be HER2-positive, as defined by ASCO/CAP 2013 guidelines [37].
• Documented disease progression (via RECIST or clinical progression) or intolerance during or
after the most recent treatment for locally advanced/metastatic breast cancer.
• Refractory or intolerant to pertuzumab (refractory to pertuzumab is defined as progression on
pertuzumab in the locally advanced or metastatic setting, or development of disease recurrence
during or within 12 months of completing pertuzumab-containing neoadjuvant and/or adjuvant
therapy).
• Disease progression on, or intolerant to, T-DM1 in the locally advanced/metastatic breast
cancer setting.
• Previously treated with trastuzumab in any setting (trastuzumab could have been previously
administered with or without pertuzumab).
General • Age ≥18 years.
• Eastern Cooperative Oncology Group performance status 0 or 1.
Hematologic, biochemical, and organ
function
• Eligible to receive at least one of gemcitabine, capecitabine, or vinorelbine.
• Adequate bone marrow reserves (absolute neutrophil count ≥1500/μL; platelet count ≥100 000/μL;
hemoglobin ≥9 g/dL [transfusions allowed]), coagulation function (INR and aPTT ≤1.5 ULN, unless
on therapeutic coagulants), hepatic function (serum total bilirubin within normal limits; AST and ALT
up to 3x ULN; serum albumin ≥2.5 g/dL), renal function (serum creatinine ≤1.5x ULN), and cardiac
function (LVEF ≥50 % by MUGA or ECHO).
Exclusion criteria
Disease-specific • Previous treatment with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other
anthracycline derivative.
• CNS metastases, unless patients have been treated and are stable without symptoms for 4 weeks
after completion of treatment, and they must be off steroids for at least 4 weeks prior to enrollment.
• Active other malignancy or history of other malignancy within the last 5 years except appropriately
treated carcinoma of the cervix, non-melanoma skin carcinoma, stage 1 uterine cancer, or cancers
with a similar curative outcome as those previously mentioned.
• Known hypersensitivity to any of the components of MM-302 or hypersensitivity reactions to fully
humanized monoclonal antibodies.
• History of intolerance to trastuzumab. Patients who have been successfully re-challenged with
trastuzumab after a mild infusion reaction are allowed.
• Investigational therapy administered <28 days (or <5 half-lives; whichever is the longest) prior to
the first scheduled day of study drug dosing.
• Any standard anticancer therapy <14 days prior to the first scheduled day of study drug dosing
(except trastuzumab).
Cardiac • Any class of NYHA congestive heart failure, or heart failure with preserved ejection fraction.
• History of known coronary artery disease or a myocardial infarction within the last 12 months.
• Uncontrolled hypertension (SBP >160 mmHg or DBP >100 mmHg).
• Unstable angina pectoris.
• Known history of serious cardiac arrhythmias requiring treatment (exception: atrial fibrillation
and paroxysmal supraventricular tachycardia).
• Prolonged QTc interval (≥450 ms).
• Previous discontinuation of trastuzumab due to unacceptable cardiac toxicity or infusion-related
reactions.
• History of LVEF decline to <50 % during or after HER2-directed therapy.
• Current dyspnea at rest that requires continuous oxygen therapy.
General • Pregnant or breast feeding.
• Active infection or unexplained fever >38.5 °C during screening visits.
• History of allogeneic transplant (patients with a history of autologous bone marrow or stem
cell transplant may be enrolled).
ALT alanine aminotransferase, aPTT activated partial thromboplastin time, ASCO American Society of Clinical Oncology, AST aspartate aminotransferase, CAP
College of American Pathologists, CNS central nervous system, CTCAE Common Terminology Criteria for Adverse Events, DBP diastolic blood pressure, ECHO
echocardiogram, HER2 human epidermal growth factor receptor 2, INR international normalized ratio, LVEF left ventricular ejection fraction, MUGA multiple-gated
acquisition scan, NYHA New York Heart Association, QTc corrected QT interval, RECIST Response Evaluation Criteria In Solid Tumors, SBP systolic blood pressure,
T-DM1 ado-trastuzumab emtansine, ULN upper limit of normal
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using the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (NCI-CTCAE) v4.0 at
screening; on days 1, 8, and 15 of cycle 1; on day 1 of every
cycle thereafter; and 30 days after treatment discontinu-
ation. Blood samples for pharmacokinetic analyses will be
taken in cycles 1 and 2 from patients randomized to
MM302 and trastuzumab; samples will be collected pre-
infusion, immediately post-infusion, 8–96 h post-infusion
(optional sample), and 168 h post-infusion. Patient quality
of life will be assessed using the FACT-B and EQ-5D in-
struments. For analysis of serum biomarkers (in patients
who consent) and anti-MM-302 immunogenicity (in the
MM-302 arm only), serum blood samples will be collected
before dosing on day 1 of cycle 1 and every cycle there-
after and 30 days after treatment discontinuation.
Statistical analysis
The planned sample size is approximately 250 patients
(125 per arm). This sample size was chosen to observe
191 events, providing at least 90 % power to detect an
approximately 60 % improvement in PFS (hazard ratio
of 0.625). The study powering assumes a median PFS of
8 months and 5 months in the experimental arm and
control arm, respectively.
Efficacy will be assessed in the intent-to-treat popula-
tion, which will include all randomized patients. Time-
to-event analyses, including the primary endpoint, will
be compared between the experimental and control
arms using a stratified log-rank test at a 2sided 5 % sig-
nificance level in the intent-to-treat population. Time-
to-event curves will be estimated using Kaplan–Meier
estimates. Hazard ratios and 95 % confidence intervals
will be estimated using Cox proportional hazard models.
Objective response rate will be assessed using a stratified
Mantel–Haenszel test. The safety population will include
all patients who receive at least one dose (including a
partial dose) of study medication; safety will be assessed
using descriptive statistics.
Discussion
The Phase 2 HERMIONE trial has been designed,
with input from the US FDA and review by the
EMA, to assess the efficacy and tolerability of MM-
302 in combination with trastuzumab, compared with
chemotherapy of physician's choice plus trastuzumab,
in anthracycline-naïve patients with HER2positive lo-
cally advanced/metastatic breast cancer previously
treated with pertuzumab or T-DM1. Recruitment to
the trial began in September 2014.
HERMIONE is investigating a patient population with
a high unmet need for effective therapies. The standard
of care for advanced/metastatic HER2-positive breast
cancer is to continue HER2-targeted therapy indefin-
itely (trastuzumab with changing chemotherapy part-
ners, or T-DM1 or lapatinib in combination with
capecitabine) [11–15]. Microtubule-targeting chemo-
therapies, including taxanes (paclitaxel, nab-paclitaxel,
and docetaxel) and vinca domain-binding agents (T-DM1,
vinorelbine, and eribulin), are frequently used. However,
common resistance mechanisms are likely to occur among
microtubule-targeted agents and especially within the spe-
cific classes [16]. These shared resistance mechanisms
Fig. 5 Examples of the most common previous treatment pathways for eligible patients
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could result in diminishing treatment benefit for patients.
In addition, successive use of microtubule-targeting agents
may pose increasing safety concerns due to cumulative
neuropathy. Apart from the microtubule-targeting agents,
the most frequently used chemotherapeutics in combin-
ation with trastuzumab include capecitabine, and gemcita-
bine [8, 15]. Many patients continue to have a good
performance status after disease progression on standard
HER2-targeted therapies and continue to be candidates
for additional treatment. Given the heterogeneity of ad-
vanced breast cancer, a mechanistically diverse range of
therapeutic options is warranted.
The study was designed to recruit anthracycline-naïve
patients following preliminary efficacy data suggesting
that treatment with MM-302 results in higher response
rates and longer median PFS in anthracycline-naïve pa-
tients, compared with those previously exposed to
anthracyclines [36, 38], consistent with published litera-
ture on PLD [26, 39, 40]. In addition, the safety con-
cerns over the use of anthracyclines in combination
with trastuzumab have led to a decline in anthracycline
use, resulting in a large pool of patients who are
anthracycline-naïve, and who have not received one of
the most active classes of chemotherapy for the treat-
ment of breast cancer [20]. The development of novel
formulations of these agents may therefore extend the
benefits of this class to this group of patients.
Patients enrolling in HERMIONE who have already
been exposed to trastuzumab will continue trastuzu-
mab treatment. As noted earlier, this is in line with the
current standard of care for HER2-positive breast can-
cer of continuing HER2-targeted therapy indefinitely
[11–15]. Supporting this practice, a separate clinical
study randomized patients with HER2-positive breast
cancer whose disease had progressed on trastuzumab
treatment to receive capecitabine alone or capecitabine
plus trastuzumab. The study results showed a signifi-
cant improvement in overall response and PFS with
capecitabine plus trastuzumab compared with capecita-
bine alone [12, 13], supporting the continued use of
trastuzumab plus chemotherapy in HER2-positive
breast cancer.
The MM-302 dose of 30 mg/m2 every 21 days was se-
lected based on safety and efficacy data from an ongoing
Phase 1 trial: MM-302 was well tolerated at doses of
30–40 mg/m2 but an increase in grade 3/4 adverse
events was observed at 50 mg/m2 administered every
4 weeks (the highest dose level evaluated) [36, 38]. The
21-day cycle for MM-302 was selected to simplify com-
bination with the approved trastuzumab regimen, as this
is also administered every 21 days [38].
The control arm will receive trastuzumab added to
chemotherapy of physician's choice, either gemcitabine,
capecitabine, or vinorelbine. These are three of the most
commonly used cytotoxic agents (besides taxanes, which
will have been used in earlier lines of therapy); they can be
combined with trastuzumab [8, 12, 13, 41–44]; and they
are recommended in treatment guidelines [11, 14, 15].
Chemotherapy of physician's choice is limited to only
three agents to minimize potential confounding of the key
outcome measures, given the relatively small sample size
required for this study. There is flexibility in the dose
ranges that physicians can use, in line with the approved
US package insert or European Summary of Product
Characteristics, and the National Comprehensive Cancer
network guidelines [15, 45–50], reflecting doses com-
monly used in the clinic.
The primary endpoint for the HERMIONE trial is PFS
as determined by a blinded independent review, based
on evidence that increases in PFS have generally trans-
lated into improvements in OS in late-line HER2-
positive advanced/metastatic breast cancer. An analysis
of approval trials in HER2-positive advanced/metastatic
breast cancer suggested a moderate correlation between
PFS and OS [51]. Furthermore, the TH3RESA trial re-
ported a PFS hazard ratio of 0.53 that corresponded with
an OS hazard ratio of 0.55 from the first interim analysis
[8]. This trial evaluated T-DM1 in HER2-positive late-
line advanced/metastatic breast cancer, and used a com-
parator arm of treatment of physician’s choice, which
was predominantly trastuzumab in combination with
chemotherapy. These data suggest that an improvement
in PFS with trastuzumab in combination with MM-302
in a similar patient population to that in TH3RESA
could likewise translate into an improvement in OS.
Conclusion
The HERMIONE trial is designed to test whether
MM-302, a novel HER2-targeted antibody–liposomal
doxorubicin conjugate, added to trastuzumab could
be an effective and welltolerated treatment option for
anthracycline-naïve patients with HER2-positive ad-
vanced/metastatic breast cancer who are candidates
for systemic therapy after disease progression on ap-
proved agents.
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